新疆百花村医药集团股份有限公司 第九届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 编号：2025-038 一、董事会会议召开情况 新疆百花村医药集团股份有限公司（以下简称"公司"）第九届董事会第八 次会议，于 2025 年 10 月 27 日北京时间 12:00，在公司 22 楼会议室以现场结合 通讯方式召开。本次会议以电子邮件的方式发出会议通知。应参会董事 11 人， 实际参会董事 11 人。会议由董事长郑彩红女士主持，会议符合《公司法》和《公 司章程》的规定，会议召开有效，公司高管列席本次会议。 二、董事会会议审议情况 1、审议通过《公司 2025 年第三季度报告》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案已经公司董事会审计委员会审议通过。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）、上海证券报 和证券日报上披露的《公司 2025 年第三季度报告》。 2、审议通过《公 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 新疆百花村医药集团股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 公司负责人郑彩红、主管会计工作负责人蔡子云及会计机构负责人（会计主管人员）余涛保证季度报告 中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 1 / 10 单位：元 币种：人民币 项目 本报告期 本报告期比上年同 期增减变动幅度 (%) 年初至报告期 末 年初至报告期末比 上年同期增减变动 幅度(%) 营业收入 96,519,541.28 2.32 298,606,173.49 2.74 利润总额 8,169,473.75 262.52 38,720,027.55 43.13 归属于上市公司股东的净利 润 7,190,825.2 ...

Core Insights - The company reported third-quarter revenue of 96.52 million yuan, representing a year-on-year increase of 2.32% [1] - Net profit for the third quarter was 7.19 million yuan, showing a significant year-on-year growth of 456.45% [1] - For the first three quarters, total revenue reached 299 million yuan, reflecting a year-on-year increase of 2.74% [1] - Net profit for the first three quarters amounted to 32.67 million yuan, which is a year-on-year increase of 36.41% [1]

Core Viewpoint - Baohua Pharmaceutical's stock has experienced fluctuations, with a notable decline of 2.08% on September 22, 2023, amidst significant trading activity and a year-to-date increase of 42.64% [1] Company Overview - Baohua Pharmaceutical, established on June 21, 1996, and listed on June 26, 1996, is located in Urumqi, Xinjiang. The company specializes in early drug discovery, CMC development, clinical trials, registration, and various pharmaceutical services [2] - The company's revenue composition includes 49.39% from clinical trials, 42.67% from pharmaceutical R&D and consistency evaluation, 6.69% from leasing and property services, and 0.94% from other income [2] - As of June 30, 2023, the number of shareholders is 30,000, a decrease of 26.42%, with an average of 12,799 circulating shares per person, an increase of 35.95% [2] Financial Performance - For the first half of 2023, Baohua Pharmaceutical reported revenue of 202 million yuan, a year-on-year increase of 2.95%, and a net profit attributable to shareholders of 25.48 million yuan, up 12.45% year-on-year [2] - The company has cumulatively distributed 6.1275 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]

Group 1 - The core viewpoint of the news is that the weight loss drug sector experienced a significant decline in stock prices after an initial rise, indicating volatility in this market segment [1] - Specifically, Borui Pharmaceutical saw a drop of over 10% after previously rising more than 9% [1] - Other companies in the sector, such as Zhongsheng Pharmaceutical, fell over 7%, while Tianenkang, Kexing Pharmaceutical, Baihua Pharmaceutical, and Jinkaishengke also experienced declines [1]

Company Overview - Baihua Medicine has seen a stock price increase of 52.05% year-to-date, with a recent 0.10% rise over the last five trading days, 16.24% over the last 20 days, and 40.93% over the last 60 days [2] - The company has appeared on the stock market's "Dragon and Tiger List" four times this year, with the most recent appearance on September 4, where it recorded a net buy of -57.5752 million yuan [2] - Baihua Medicine's main business includes early drug discovery, drug CMC development, clinical trials, registration applications, and various pharmaceutical services [2] Financial Performance - As of June 30, the number of shareholders for Baihua Medicine was 30,000, a decrease of 26.42% from the previous period, while the average circulating shares per person increased by 35.95% to 12,799 shares [3] - For the first half of 2025, Baihua Medicine reported revenue of 202 million yuan, a year-on-year increase of 2.95%, and a net profit attributable to shareholders of 25.4834 million yuan, up 12.45% year-on-year [3] Revenue Composition - The revenue composition of Baihua Medicine is as follows: clinical trials account for 49.39%, pharmaceutical research and consistency evaluation for 42.67%, leasing and property services for 6.69%, and other income for 0.94% [2] Market Activity - On September 18, Baihua Medicine's stock price fell by 2.05% to 10.02 yuan per share, with a trading volume of 278 million yuan and a turnover rate of 7.07% [1] - The net inflow of main funds was 4.0879 million yuan, with large orders accounting for 19.69% of purchases and 18.16% of sales [1]

Group 1 - The core viewpoint of the news is that Baihua Pharmaceutical has shown significant stock performance, with a year-to-date increase of 55.54% and a recent rise of 4.38% over the last five trading days [1] - As of September 17, the stock price reached 10.25 yuan per share, with a total market capitalization of 3.942 billion yuan [1] - The company has experienced net outflows of main funds amounting to 8.9312 million yuan, with large orders showing a buy-sell ratio of 20.26% to 21.06% [1] Group 2 - Baihua Pharmaceutical, established on June 21, 1996, specializes in early drug discovery, CMC development, clinical trials, and various pharmaceutical services [2] - The company's revenue composition includes 49.39% from clinical trials, 42.67% from drug research and consistency evaluation, and 6.69% from leasing and property services [2] - As of June 30, the number of shareholders decreased by 26.42% to 30,000, while the average circulating shares per person increased by 35.95% to 12,799 shares [2] Group 3 - Since its A-share listing, Baihua Pharmaceutical has distributed a total of 6.1275 million yuan in dividends, with no dividends paid in the last three years [3]

Company Overview - Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. is located in Urumqi, Xinjiang, and was established on June 21, 1996, with its listing date on June 26, 1996 [2] - The company specializes in early drug discovery and screening, drug CMC development, clinical trials, registration applications, bio-sample analysis, and pharmaceutical testing services, providing a comprehensive outsourcing and technology transfer service [2] - The main business revenue composition includes: clinical trials 49.39%, pharmaceutical R&D and consistency evaluation 42.67%, leasing and property services 6.69%, and other income 0.94% [2] Financial Performance - For the first half of 2025, the company achieved operating revenue of 202 million yuan, a year-on-year increase of 2.95%, and a net profit attributable to the parent company of 25.48 million yuan, a year-on-year increase of 12.45% [2] - As of June 30, the number of shareholders was 30,000, a decrease of 26.42% from the previous period, while the average circulating shares per person increased by 35.95% to 12,799 shares [2] Stock Performance - On September 16, the stock price of Baihua Pharmaceutical fell by 2.07% to 9.92 yuan per share, with a trading volume of 76.24 million yuan and a turnover rate of 1.98%, resulting in a total market capitalization of 3.815 billion yuan [1] - Year-to-date, the stock price has increased by 50.53%, with a recent decline of 2.27% over the last five trading days, a 13.24% increase over the last 20 days, and a 36.26% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on September 4, where it recorded a net buy of -57.5752 million yuan [1] Dividend Information - Since its A-share listing, the company has distributed a total of 6.1275 million yuan in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - Baohua Pharmaceutical has shown significant stock performance with a year-to-date increase of 55.08%, despite a recent decline in the last five trading days [1] Group 1: Stock Performance - As of September 12, Baohua Pharmaceutical's stock price was 10.22 CNY per share, with a market capitalization of 3.93 billion CNY [1] - The stock has experienced a 5.89% decline over the last five trading days, but a 28.07% increase over the last 20 days and a 45.79% increase over the last 60 days [1] - The company has appeared on the trading leaderboard four times this year, with the most recent appearance on September 4, where it recorded a net buy of -57.58 million CNY [1] Group 2: Company Overview - Baohua Pharmaceutical, established on June 21, 1996, is located in Urumqi, Xinjiang, and was listed on June 26, 1996 [2] - The company specializes in early drug discovery, drug CMC development, clinical trials, registration, and various pharmaceutical services, providing a comprehensive outsourcing and technology transfer service [2] - The revenue composition includes clinical trials (49.39%), pharmaceutical R&D and consistency evaluation (42.67%), leasing and property services (6.69%), and other income (0.94%) [2] Group 3: Financial Performance - For the first half of 2025, Baohua Pharmaceutical reported revenue of 202 million CNY, a year-on-year increase of 2.95%, and a net profit attributable to shareholders of 25.48 million CNY, up 12.45% year-on-year [2] - The company has distributed a total of 6.13 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-037 新疆百花村医药集团股份有限公司（以下简称"公司"）于 2025 年 9 月 8 日召开第九届董事会第七次会议，审议通过了《公司关于调整第九届董事会专门 委员会成员的议案》。 公司董事孙建斌先生于 2025 年 7 月 17 日辞职，2025 年 9 月 8 日，公司股 东会审议通过《公司关于补选董事的议案》，聘任赵佳佳女士为公司董事。孙建 斌先生在公司董事会专门委员会担任的职务由赵佳佳女士接任，调整后的专门委 员会成员如下： 一、审计委员会成员： 主任委员：谷莉 成员：陆群威、陆星宇、郑彩红、赵佳佳 二、薪酬与考核委员会成员： 主任委员：陆群威 新疆百花村医药集团股份有限公司董事会 新疆百花村医药集团股份有限公司 关于调整第九届董事会专门委员会成员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 成员：谷莉、李文宝、吕政田、赵佳佳 特此公告。 2025 年 9 月 9 日 ...